Clinical trial data from the NEJM Phase 2 study showed that gastrointestinal events were predominantly mild to moderate, occurred primarily during dose escalation, and were partially mitigated by starting at 2mg rather than 4mg
Several studies have attempted to shed light on the potential pro-angiogenic mechanism of BPC-157
Cortagen targets the cerebral cortex and may support neurological function in lupus patients who experience neuropsychiatric symptoms, a feature present in up to 75% of SLE patients at some point in their disease course
Weight loss with peptides is not an overnight process
Sustained benefits suggest successful healing
The nurse remained in the treatment room for a considerable portion of the total time discussing products, expected results, time until effects felt, and related medical issues because she had time to do so